Expert discusses how the prevalence of chronic kidney disease (CKD), as reflected by decreased estimated glomerular ...

Phenylalanine hydroxylase (PheOH) catalyzes the conversion of phenylalanine to tyrosine, a rate-limiting step in phenylalanine catabolism and protein and neurotransmitter biosynthesis (for recent ...

The benefits of SGLT2 inhibitors on kidney disease progression in individuals irrespective of diabetes or albuminuria status ...

Nearly all adults with chronic kidney disease would benefit from a systolic blood pressure target of less than 120 versus less than 140 mm Hg.

Good morning, ladies and gentlemen. Welcome to the Greenfire Resources Third Quarter 2025 Results Conference Call. [Operator Instructions] The conference is being recorded. [Operator Instructions].

Although SGLT2 inhibitors are standard-of-care treatments for CKD, type 2 diabetes, and heart failure (HF), the drugs are underutilized in clinical practice.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...

Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...

Stroke, once considered a disease of old age, is increasingly seen in younger adults. While hypertension and diabetes continue to be the leading risk factors, new evidence points towards chronic sleep ...